Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
- Conditions
- Interventions
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT03679650
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 14
- Registration Number
- NCT03663751
- Locations
- 🇨🇳
Blood & Marrow Transplantation Center, RuiJin Hospital, Shanghai, Shanghai, China
Quizartinib, Decitabine, and Venetoclax in Treating Participants with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 73
- Registration Number
- NCT03661307
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 122
- Registration Number
- NCT03596892
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Mingzhi Zhang
- Target Recruit Count
- 60
- Registration Number
- NCT03579082
- Locations
- 🇨🇳
Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Mingzhi Zhang
- Target Recruit Count
- 40
- Registration Number
- NCT03558412
- Locations
- 🇨🇳
Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Southwest Hospital, China
- Target Recruit Count
- 100
- Registration Number
- NCT03553537
Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT03530085
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-09-05
- Target Recruit Count
- 119
- Registration Number
- NCT03467178
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 22
- Registration Number
- NCT03445858
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.